UNH Receives $1.8 Million For Biomolecular Research in Diabetes and Cancer

The University of New Hampshire will receive $1.8 million from the National Institutes of Health (NIH) that will further molecular research to better understand drug interactions at the cellular level and help lead to the development of new targeted drugs to treat wide-spread metabolic, growth, neurological and visual disorders including diabetes and cancer.

Read more

Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

Read more